Physician profile
David L Shepherd
NPI 1730166893
$2,846.38
in general payments reported to CMS, 2019-2025
39 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $275 · 2020: $51.09 · 2021: $15.56 · 2022: $215 · 2024: $1,180 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $435.82 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Abbvie INC. | $213.22 | 2019-2025 | |
| Urogen Pharma, INC. | $203.25 | 2022-2025 | |
| Astellas Pharma US INC | $200.71 | 2019-2024 | Xtandi |
| Verity Pharmaceuticals INC. | $190.44 | 2024-2025 | Trelstar |
| Sumitomo Pharma America, INC. | $146.19 | 2024-2025 | Orgovyx, Gemtesa |
| Medtronic, INC. | $141.68 | 2024-2025 | Interstim, Emprint |
| Stryker Corporation | $123.21 | 2024 | Mako |
| Novartis Pharmaceuticals Corporation | $89.59 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $74.19 | 2019-2025 | Keytruda |
| Olympus America INC. | $71.99 | 2024-2025 | Itind System |
| Boston Scientific Corporation | $67.31 | 2019-2024 | Lithovue |
| Dendreon Pharmaceuticals LLC | $63.12 | 2019-2022 | |
| Convatec INC. | $55.11 | 2025 | |
| Blue Earth Diagnostics | $54.45 | 2019-2025 | Posluma |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.